Nxera Pharma Co., Ltd. (4565.T)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Christopher Cargill
|
Representative Executive Officer, President, CEO & Chairman | 150M | -- | 1984 |
|
Mr. Hironoshin Nomura
|
Executive Officer & CFO | 68M | -- | 1983 |
|
Dr. Shinichi Tamura
|
Founder | 233M | -- | 1949 |
|
Mr. Toshihiro Maeda
|
President of Nxera Pharma Japan & COO | -- | -- | 1979 |
|
Mr. Kieran Johnson F.C.A.
|
Executive Officer & Chief Accounting Officer | 83M | -- | 1969 |
|
Dr. Patrik Foerch Ph.D.
|
Chief Scientific Officer, President of Nxera Pharma UK & Director | -- | -- | -- |
|
Mr. Shinya Tsuzuki
|
Head of Investor Relations | -- | -- | 1993 |
|
Ms. Mariko Nakafuji
|
Executive VP & Chief Legal Officer | -- | -- | -- |
|
Mr. Shinichiro Nishishita
|
VP of Investor Relations & Head of Regulatory Disclosures | -- | -- | -- |
|
Stacey Southall
|
Associate Director & Head of Biophysics | -- | -- | -- |
Nxera Pharma Co., Ltd.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 314
Description
Nxera Pharma Co., Ltd. operates as a biopharmaceutical company, engages in drug discovery and development in Japan, the United States, Germany, Switzerland, Bermuda, the United Kingdom, and internationally. The company offers NxWave, a GPCR-targeted structure-based drug discovery platform; PIVLAZ for the cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aSAH; and QUVIVIQ for insomnia. It develops NBI-1117568, an muscarinic M4 agonist in phase 3 trial for schizophrenia, dementia and other neuropsychiatric disorders; ORX750, an OX2 agonist for narcolepsy, idiopathic hypersomnia, and other sleep-wake disorders; NBI-1117570, a dual muscarinic M1/M4 agonist; and HTL0039732, an EP4 antagonist immunotherapy drug. The company's products in phase 1 trial include PF-07054894, a CCR6 antagonist and NXE0033744, an EP4 agonist for inflammatory bowel disease; PF-07258669, a MC4 antagonist for anorexia; NBI-1117569, a muscarinic M4-preferring agonist, and NBI-1117567, a muscarinic M1 agonist for major central nervous system disorders; TMP-301, a mGlu5 NAM for substance use disorders; and NXE0048149, a GPR52 agonist for schizophrenia. Its products in preclinical trial comprise KY1051, a CXCR4 mAb for immuno-oncology; and NXE0027477, a GPR35 agonist for inflammatory bowel disease and GI disorders. The company also develops other discovery-stage drugs. It has strategic collaborations with Tempero Bio, Pharmenable Therapeutics, Antiverse, Sanofi, Cancer Research UK, Centessa Pharmaceuticals, Lilly, AbbVie, Genentech, Pfizer, Neurocrine Biosciences, Antiverse, and Novartis International AG. The company was formerly known as Sosei Group Corporation. Nxera Pharma Co., Ltd. was incorporated in 1990 and is headquartered in Minato, Japan.
Corporate Governance
Upcoming Events
October 30, 2026 at 6:30 AM UTC
Nxera Pharma Co., Ltd. Earnings Date
Recent Events
March 27, 2015 at 12:00 AM UTC
Ex-Dividend Date
